A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer1

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Immunology

• Publication date

  2009-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.4049/jimmunol.0800126PMID 19201905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer

  2008cited by this paper
• Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.

  2008cited by this paper
• Clinical applications of natural killer T cell–based immunotherapy for cancer

  2008cited by this paper
• Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.

  2007cited by this paper
• Migration of Tumor Antigen-Pulsed Dendritic Cells After Mucosal Administration in the Human Upper Respiratory Tract

  2007cited by this paper
• The biology of NKT cells.

  2007cited by this paper
• Natural killer T cell‐mediated antitumor immune responses and their clinical applications

  2006cited by this paper
• A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

  2006cited by this paper
• Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.

  2005cited by this paper
• A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.

  2005cited by this paper
• Increased Intratumor Vα24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal Carcinomas

  2005cited by this paper
• A Phase I Study of α-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

  2005cited by this paper
• Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients

  2005cited by this paper
• Dendritic cell maturation by CD11c− T cells and Vα24+ natural killer T‐cell activation by α‐Galactosylceramide

  2005cited by this paper
• Autologous dendritic cell vaccines for non-small-cell lung cancer.

  2004cited by this paper
• Multidisciplinary management of lung cancer.

  2004cited by this paper
• Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen

  2004cited by this paper
• Therapeutic activation of Vα24^+Vβ11^+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

  2004cited by this paper
• NKT cells: what's in a name?

  2004cited by this paper
• Multidisciplinary management of lung cancer.

  2004cited by this paper
• CD1: antigen presentation and T cell function.

  2004cited by this paper
• Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses

  2004cited by this paper
• The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune Response

  2003cited by this paper
• The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer.

  2003cited by this paper
• The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

  2003cited by this paper
• The NKT cell system: bridging innate and acquired immunity

  2003cited by this paper
• Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein

  2003cited by this paper
• Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer Staining

  2002cited by this paper
• Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells

  2002cited by this paper
• Vα24-JαQ-Independent, CD1d-Restricted Recognition of α-Galactosylceramide by Human CD4+ and CD8αβ+ T Lymphocytes1

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002influential reference
• Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.

  2002cited by this paper
• Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.

  2002cited by this paper
• IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.

  2002cited by this paper
• Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes.

  2002cited by this paper
• Preserved IFN‐α production of circulating Vα24 NKT cells in primary lung cancer patients

  2002cited by this paper
• IFN-γ–mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide

  2002cited by this paper
• Leucocyte typing VII : white cell differentiation antigens : proceedings of the seventh international workshop and conference held in Harrogate, United Kingdom

  2002cited by this paper
• Preserved IFN-γ production of circulating Vα24 NKT cells in primary lung cancer patients

  2002cited by this paper
• TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.

  2001cited by this paper
• Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells

  2000cited by this paper
• Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review.

  2000cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Tracking the Response of Natural Killer T Cells to a Glycolipid Antigen Using Cd1d Tetramers

  2000cited by this paper
• CD1d-restricted and TCR-mediated activation of V α14 NKT cells by glycosylceramides

  2000cited by this paper
• CD1d structure and regulation on human thymocytes, peripheral blood T cells,B cells and monocytes

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Antitumor Cytotoxicity Mediated by Ligand-activated Human Vα24 NKT Cells

  1999cited by this paper
• Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells.

  1999cited by this paper
• Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.

  1999cited by this paper
• Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells.

  1999cited by this paper
• CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution

  1998cited by this paper
• CD1d-restricted Recognition of Synthetic Glycolipid Antigens by Human Natural Killer T Cells

  1998cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.

  1997cited by this paper
• Leucocyte Typing III: White Cell Differentiation Antigens

  1988cited by this paper

• Artificial thymic organoid culture generates functional iPSC-derived CD4+ invariant natural killer T cells

  2026cites this paper
• Unconventional T Cells’ Role in Cancer: Unlocking Their Hidden Potential to Guide Tumor Immunity and Therapy

  2025cites this paper
• Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial

  2025cites this paper
• Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy

  2025cites this paper
• Development of potential immunomodulatory ligands targeting natural killer T cells inspired by gut symbiont-derived glycolipids

  2025cites this paper
• Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer.

  2025cites this paper
• Generation of iPSC-Derived iNKT Cells with Pro-Hematopoietic Activity

  2025cites this paper
• Characteristics of Peripheral Blood Lymphocyte Populations in Patients with Locally Advanced Unresectable Non-Small Cell Lung Cancer

  2025cites this paper
• Unveiling the significance of inducible nitric oxide synthase: its impact on cancer progression and clinical implications.

  2024cites this paper
• NKT-Licensed In Vivo Dendritic Cell-Based Immunotherapy as Cellular Immunodrugs for Cancer Treatment.

  2024cites this paper
• T Cell Receptor-Engaging Monoclonal Antibodies Mobilize the Anti-Tumor Functions of Invariant Natural Killer T Cells.

  2024cites this paper
• Prognostic impact of invariant natural killer T cells in solid and hematological tumors; systematic review and meta-analysis

  2024cites this paper
• Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy

  2024cites this paper
• Immunotherapy for hepatocellular carcinoma

  2024cites this paper
• Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner

  2024cites this paper
• 肿瘤相关巨噬细胞：调节肿瘤微环境的新靶点

  2024cites this paper
• Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ

  2024cites this paper
• The α glycolipid rules the NKT cell TCR

  2024cites this paper
• Traversing the bench to bedside journey for iNKT cell therapies

  2024cites this paper
• Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer

  2023cites this paper
• Lipid Metabolism in the Immune Niche of Tumor-Prone Liver Microenvironment.

  2023cites this paper
• Augmenting Granzyme B–Expressing NK Cells by Invariant NKT Ligand–Loaded APCs in Patients with Postoperative Early Stage Non–Small Cell Lung Cancer: Results of a Randomized Phase II Study

  2023cites this paper
• Expansion of mixed immune cells using CD3/CD161 co-stimulation for the treatment of cancer

  2023cites this paper
• Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas

  2023cites this paper
• Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results

  2023cites this paper
• Role of NKT cells in cancer immunotherapy—from bench to bed

  2022cites this paper
• Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model

  2022cites this paper
• iNKT: A new avenue for CAR-based cancer immunotherapy

  2022cites this paper
• Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression

  2022cites this paper
• Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML

  2022cites this paper
• Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial.

  2022cites this paper
• Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment

  2022cites this paper
• Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.

  2022cites this paper
• The interaction between iNKT cells and B cells

  2021cites this paper
• Identifying, Isolation, and Functional Use of Human Liver iNKT Cells.

  2021cites this paper
• Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds

  2021cites this paper
• Targeting “Natural Born Killers” to Modulate Immune Suppression in Neurocritical Care

  2021cites this paper
• Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy

  2021cites this paper
• Targeting Natural Killer T Cells in Solid Malignancies

  2021cites this paper
• Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ

  2021cites this paper
• The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead

  2021cites this paper
• Liver X receptors regulate natural killer T cell population and antitumor activity in the liver of mice

  2021cites this paper
• NK and NKT cells have distinct properties and functions in cancer

  2021cites this paper
• Targeting Sphingolipids for Cancer Therapy

  2021cites this paper
• Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice

  2021cites this paper
• Successes and challenges of NKT cell immunotherapy: Breaking tolerance to cancer resistance

  2021cites this paper
• Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

  2021cites this paper
• Phototherapy Facilitates Tumor Recruitment and Activation of Natural Killer T cells for Potent Cancer Immunotherapy.

  2021cites this paper
• Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer

  2020cites this paper
• Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses

  2020cites this paper
• Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody

  2020cites this paper
• Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer

  2020cites this paper
• Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies

  2020cites this paper
• Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d‐independent manner

  2020cites this paper
• A phase I study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer.

  2020cites this paper
• CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies

  2020cites this paper
• CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy

  2020cites this paper
• Using agonists for iNKT cells in cancer therapy.

  2020cites this paper
• 頭頸部癌に対する NKT 細胞を利用したワクチン治療

  2020cites this paper
• Cytotoxic and Antitumor Compounds from Marine Invertebrates

  2020cites this paper
• α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice

  2020cites this paper
• Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells

  2020cites this paper
• Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis

  2020cites this paper
• Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer

  2019cites this paper
• Immune Networks and Therapeutic Targeting of iNKT Cells in Cancer.

  2019cites this paper
• Roles of NKT cells in cancer immunotherapy

  2019cites this paper
• Innate T cells in the intensive care unit.

  2019cites this paper
• Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.

  2019cites this paper
• Synthesis of 5-Thio-α-GalCer Analogues with Fluorinated Acyl Chain on Lipid Residue and Their Biological Evaluation.

  2019cites this paper
• Generation of a Jurkat-based fluorescent reporter cell line to evaluate lipid antigen interaction with the human iNKT cell receptor

  2019cites this paper
• Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma

  2019cites this paper
• Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy

  2018cites this paper
• Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors

  2018cites this paper
• Tissue-specific functions of invariant natural killer T cells

  2018cites this paper
• NKT cells — New players in CAR cell immunotherapy?

  2018cites this paper
• The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional Approach

  2018cites this paper
• The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens

  2018cites this paper
• Regulation of Humoral Immunity by CD1d-Restricted Natural Killer T Cells

  2018cites this paper
• Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer

  2018cites this paper
• Role of leukotriene B4 12-hydroxydehydrogenase in α-galactosylceramide-pulsed dendritic cell therapy for non-small cell lung cancer.

  2018cites this paper
• Lipid-Reactive T Cells in Immunological Disorders of the Lung

  2018cites this paper
• Roles of the immune system in cancer: from tumor initiation to metastatic progression

  2018cites this paper
• CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

  2018cites this paper
• Potential advantages of CD1‐restricted T cell immunotherapy in cancer

  2018cites this paper
• NKT cells in liver diseases

  2018cites this paper
• Unconventional T Cell Targets for Cancer Immunotherapy.

  2018influential citation
• Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy

  2017cites this paper
• Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective

  2017cites this paper
• Optimisation de l'activité immunostimulatrice des lymphocytes T Natural Killer invariants : conséquences sur l'immunité anti-tumorale

  2017cites this paper
• THE ROLES OF CHEMOKINES, CHEMOKINE RECEPTORS AND GLYCOLIPID ACTIVATION IN NKT CELL TUMOUR INFILTRATION

  2017cites this paper
• Efficient Production of Functional Human NKT Cells from Induced Pluripotent Stem Cells - Reprogramming of Human Vα24+iNKT Cells.

  2017cites this paper
• Development and anti-tumor effects of lung cancer stem cell chaperon molecule antigen peptide vaccine

  2017cites this paper
• Innate immune cells for immunotherapy of autoimmune and cancer disorders

  2017cites this paper
• Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial

  2017cites this paper
• Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

  2017influential citation
• NKT-cell glycolipid agonist as adjuvant in synthetic vaccine.

  2017cites this paper
• Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity

  2017cites this paper
• Induction of antitumor response to fibrosarcoma by Newcastle disease virus-infected tumor vaccine

  2017cites this paper
• Natural Killer T Cells in Cancer Immunotherapy

  2017cites this paper
• Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer

  2017cites this paper